Breaking News

Agenus, Merck in Antibody Development Pact

April 28, 2014

To develop therapeutic antibodies for cancer treatments

Agenus Inc. has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for cancer treatments. Agenus will be responsible for discovery and optimization of fully human antibodies against two undisclosed Merck targets using the 4-Antibody Retrocyte Display platform. Merck will be responsible for clinical development and commercialization.
 
Agenus is eligible to receive approximately $100 million in payments associated with the clinical, regulatory and commercial milestones for two candidates, as well as royalties on worldwide product sales.
 
“We are delighted to be working with Merck, who is a leader in the rapidly developing immuno-oncology space," said Bob Stein, MD, Ph.D., chief scientific officer of Agenus. "We believe our Retrocyte Display technology has significant advantages for creation of high quality antibody development candidates. This collaboration broadens our efforts in immuno-oncology beyond our previously disclosed checkpoint programs with a world-class research and development partner."
 
“This collaboration with Agenus complements our active immuno-oncology discovery programs,” said Dr. Eric Rubin, vice president clinical oncology, Merck Research Laboratories. “We look forward to working to advance these programs with the potential to address the unmet medical needs of people with cancer.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.